SCG Cell Therapy Partners with A*STAR BTI and NATi to Advance RNA-Based Therapeutics

Korea's National Bio Big Data Project: Advancing Precision Medicine with Macrogen and Illumina

GST Exemption Announced for Cancer Treatment Gene Therapy

AIIMS Develops Affordable CAR-T Cell Therapy for Multiple Myeloma

Sangamo Therapeutics and Astellas Collaborate on Innovative Gene Therapy for Neurological Diseases

FDA Clears IND for Arbor Biotechnologies’ ABO-101 Gene Editing Therapeutic for Primary Hyperoxaluria Type 1

Fortis Healthcare Acquires Stake in Agilus Diagnostics

FDA Approves BRAFTOVI® Combination Regimen as First-Line Treatment for BRAF V600E-Mutant Metastatic Colorectal Cancer

The Role of Big Data in Precision Medicine

Caris Life Sciences Celebrates 1,000+ Precision Medicine Studies, Advancing Cancer Research and Patient Outcomes

OncoHelix and Qualisure Diagnostics Partner to Bring Thyroid GuidePx® Test to Canadian Patients

Gates Foundation Invests $50 Million in Tessera Therapeutics to Advance Gene Therapy for Sickle Cell Disease

FDA Approves Ensartinib (Ensacove) as First-Line Treatment for ALK-Positive NSCLC

Guardant Health and Boehringer Ingelheim Collaborate to Advance Liquid Biopsy CDx for HER2-Targeted Therapy in NSCLC

Cartherics Receives $300K G-Rex Grant to Advance Cancer Cell Therapy Manufacturing

Home
/
update
/
details

Sysmex Expands Strategic Alliance with QIAGEN to Advance Genetic Testing Collaboration

NextEdge Admin

08 Aug 2024

1 min 51 sec

Sysmex Corporation has expanded its strategic alliance with QIAGEN N.V. to enhance their collaboration in genetic testing, covering research and development, production, clinical development, and sales-marketing.

Since their initial partnership in 2013 and the strategic alliance for companion diagnostics in 2021, Sysmex and QIAGEN have successfully collaborated. The expanded alliance will leverage their respective strengths in genetic testing to deliver high-value products globally. Sysmex will utilize QIAGEN’s assays for clinical trials conducted by pharmaceutical companies and research institutions at Sysmex's global network laboratories, including Sysmex Inostics, Inc. CLIA lab, Sysmex Research and Development Center, and RIKEN GENESIS Co., Ltd.

For over 50 years, Sysmex has advanced its global presence in in vitro diagnostics, focusing on personalized medicine and liquid biopsy technology. With world-class laboratories in Japan and the U.S., Sysmex aims to accelerate high-value testing and diagnostic technology development.

QIAGEN, a pioneer in precision medicine, collaborates with pharmaceutical and biotech companies to develop companion diagnostics that detect genetic abnormalities, aiding clinical decision-making. Offering technologies from PCR to next-generation sequencing (NGS), QIAGEN tailors products to pharmaceutical needs, with collaboration agreements with over 30 global pharma companies.